{"id":161955,"date":"2026-11-17T21:45:13","date_gmt":"2026-11-17T21:45:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/161955\/"},"modified":"2026-11-17T21:45:13","modified_gmt":"2026-11-17T21:45:13","slug":"roches-wilserdly-joins-oral-serd-market-but-adjuvant-indication-still-pending","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/161955\/","title":{"rendered":"Roche\u2019s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending"},"content":{"rendered":"<p><a aria-label=\"Scrip home\" class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" height=\"70px\" src=\"https:\/\/insights.citeline.com\/pf\/resources\/images\/sectionsLogo\/scrip.svg?d=172\" alt=\"Scrip logo\"\/><\/a><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\/anticancer\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\/anticancer\/immuno-oncology\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p class=\"c-paragraph b-subheadline-paragraph\">Roche\u2019s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining three other oral SERDs on the market. <\/p>\n<p><img decoding=\"async\" data-chromatic=\"ignore\" alt=\"breast cancer\" class=\"c-image\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/4UF6SG45OJGYXCIKOLGC4N2KEI.jpg\" width=\"700\" height=\"394\"\/>Roche has a new drug approved for breast cancer (Shutterstock) Key TakeawaysRoche\u2019s Wilserdly (giredestrant) is the fourth next-generation oral selective estrogen receptor degrader (SERD) to reach the market for ESR1-mutated, ER+, HER2- advanced or metastatic breast cancer after endocrine therapy.<\/p>\n<p class=\"editor-paragraph\">\u00a0<\/p>\n<p class=\"c-paragraph\">Roche\u2019s Wilserdly (giredestrant) was approved by the US Food and Drug Administration as the fourth next-generation oral selective estrogen receptor&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"Roche\u2019s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining&hellip;\n","protected":false},"author":2,"featured_media":161956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[75321,75322,3658,134,75132],"class_list":["post-161955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-er","tag-her2-breast-cancer","tag-oral-serd","tag-roche","tag-wilserdly"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117633975825721377","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/161955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=161955"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/161955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/161956"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=161955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=161955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=161955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}